Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital Analyst Bryan Abraham says Sarapta’s shares (Variety) Can trade a lower FDA database today, which includes a patient’s patient’s death in November, who experienced muscle spasms and Mylagia.
Published in the first place Penurious – The final source of real-time, market moving financial news. Try now >>
See Hot Resets of Insider on Tipranks >>
Read more in Srpt: